@article{article, title  = {{Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma}},

 url = {{https://eprints.whiterose.ac.uk/101665/ }},

 year = {{2016}},

 month = {{5}},

 author = {{Powles T and Lackner MR and Oudard S and Escudier B and Ralph C and Brown JE and Hawkins RE and Castellano D and Rini BI and Staehler MD and Ravaud A et al}},

 doi = {{10.1200/JCO.2015.64.8808}},

 volume = {{34}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{14}},

 pages = {{1660-1668}},

 note = {{Accessed on 2024/12/27}}}